COMMONWEALTH OF KENTUCKY
CABINET FOR HEALTH AND FAMILY SERVICES
DEPARTMENT FOR MEDICAID SERVICES
PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE MEETING
NOTE: This special called meeting will be held virtually via Microsoft Teams webinar.
Tuesday, July 15, 2025
1:00 P.M. to 4:00 P.M. (Eastern)

Smartphone/Web	Dial-In
Join the meeting now Meeting ID: 225 141 803 542 Passcode: nP249PC2 Download Teams | Join on the web	+1-858-252-2734 (US Toll) Phone Conference ID: 991 316 184#

AGENDA

I. Call to Order and Welcome

II. Executive Session (upon request)

III. Old Business
- a. Approval of January 2025 Meeting Minutes
- b. Approval of April 2025 Meeting Minutes

IV. New Business
- a. New Products to Market to be Reviewed as Single Products:
  - i. Zunveyl® *(Alzheimer's Agents)*
  - ii. Qfitlia™ *(Non-PDL)*
  - iii. Ryzneuta® *(Colony Stimulating Factors)*
  - iv. Vanrafia® *(Non-PDL)*

V. New Therapeutic Class
- a. Antimigraine Agents, CGRP Inhibitors & Other Agents: Acute Treatment
- b. Antimigraine Agents, CGRP Inhibitors & Other Agents: Prophylaxis
  - a. Injectable
  - b. Oral

VI. Therapeutic Classes with Recommended Changes
- a. Bladder Relaxants
- b. Narcolepsy Agents
- c. Skeletal Muscle Relaxants
- d. Stimulants & Related Agents
- e. Glucagon Agents

Copyright © 2023 MedImpact Healthcare Systems, Inc. All rights reserved.

VII. Consent Agenda

a. The following therapeutic classes have no changes recommended and may be voted on as a group under a consent agenda:

• Angiotensin-Converting Enzyme (ACE) Inhibitors • ACEI + Diuretic Combinations • Angiotensin Modulator + Calcium Channel Blocker (CCB) Combinations • Angiotensin Receptor Blockers (ARBs) • Antianginal & Anti-Ischemic • Antiarrhythmics, Oral • Anticoagulants • ARB + Diuretic Combinations • Beta-Blockers • Calcium Channel Blockers (CCBs) • Direct Renin Inhibitors • Lipotropics, Other • Lipotropics, Statins • PAH Agents – Oral and Inhaled • Platelet Aggregation Inhibitors • Alzheimer's Agents • Anticonvulsants • Antidepressants, Monoamine Oxidase Inhibitors • Antidepressants, Other • Antidepressants, SNRIs	• Antidepressants, SSRIs • Antidepressants, Tricyclics • Antimigraine Agents, CGRP Inhibitors & Other Agents: Acute Treatment • Antimigraine Agents, CGRP Inhibitors & Other Agents: Prophylaxis - Injectable • Antimigraine Agents, CGRP Inhibitors& Other Agents: Prophylaxis - Oral • Antimigraine Agents -Triptans • Antiparkinson's Agents • Antipsychotics, First Generation • Antipsychotics, Second Generation: Oral and Injectable • Anxiolytics • Dopamine Receptor Agonists • Movement Disorders • Neuropathic Pain • Sedative Hypnotics • Tobacco Cessation Products • 5-Alpha Reductase Inhibitors • Alpha Blockers For Benign Prostatic Hyperplasia (BPH)

VIII. Adjournment

a. Schedule of Upcoming Meetings
   i. **October 14, 2025**

To view the most current Preferred Drug List (PDL) and Prior Authorization (PA) criteria, please go to https://kyportal.medimpact.com/provider-documents/drug-information.

PUBLIC SPEAKERS: If you would like to speak during the public session, please complete the Speaker Request form located on the Committee Information tab under the Forms section at https://kyportal.medimpact.com/provider-documents/pt-committee.

Copyright © 2023 MedImpact Healthcare Systems, Inc. All rights reserved.